Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare OTCMKTS:CURLF NASDAQ:CYTK NASDAQ:MRUS NASDAQ:RNA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCURLFCuraleaf$3.27+4.0%$2.61$0.68▼$3.65$2.19B0.71847,323 shs523,270 shsCYTKCytokinetics$59.71-1.5%$44.12$29.31▼$61.19$7.16B0.671.93 million shs735,478 shsMRUSMerus$94.37+0.1%$70.07$33.19▼$94.56$7.14B1.261.18 million shs1.80 million shsRNAAvidity Biosciences$46.48+0.6%$44.06$21.51▼$56.00$6.76B0.972.07 million shs361,255 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCURLFCuraleaf+4.29%-1.86%+10.88%+225.77%+5.51%CYTKCytokinetics+6.44%+12.53%+14.39%+77.05%+6.99%MRUSMerus-0.02%+0.64%+39.72%+80.15%+82.06%RNAAvidity Biosciences-1.74%+8.33%-8.30%+57.88%-2.37%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCURLFCuraleaf$3.27+4.0%$2.61$0.68▼$3.65$2.19B0.71847,323 shs523,270 shsCYTKCytokinetics$59.71-1.5%$44.12$29.31▼$61.19$7.16B0.671.93 million shs735,478 shsMRUSMerus$94.37+0.1%$70.07$33.19▼$94.56$7.14B1.261.18 million shs1.80 million shsRNAAvidity Biosciences$46.48+0.6%$44.06$21.51▼$56.00$6.76B0.972.07 million shs361,255 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCURLFCuraleaf+4.29%-1.86%+10.88%+225.77%+5.51%CYTKCytokinetics+6.44%+12.53%+14.39%+77.05%+6.99%MRUSMerus-0.02%+0.64%+39.72%+80.15%+82.06%RNAAvidity Biosciences-1.74%+8.33%-8.30%+57.88%-2.37%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCURLFCuraleaf 4.00Strong BuyN/AN/ACYTKCytokinetics 2.76Moderate Buy$76.6428.37% UpsideMRUSMerus 2.16Hold$93.12-1.32% DownsideRNAAvidity Biosciences 2.95Moderate Buy$68.3246.99% UpsideCurrent Analyst Ratings BreakdownLatest CURLF, CYTK, MRUS, and RNA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/6/2025CYTKCytokineticsBarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$71.00 ➝ $82.0010/6/2025MRUSMerusLeerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform ➝ Market Perform$95.00 ➝ $97.0010/5/2025MRUSMerusLeerink PartnrsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold10/2/2025CYTKCytokineticsBank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetNeutral$52.00 ➝ $56.009/30/2025MRUSMerusUBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Neutral$72.00 ➝ $97.009/30/2025MRUSMerusBMO Capital MarketsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeOutperform ➝ Hold9/30/2025MRUSMerusBarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight ➝ Equal Weight$112.00 ➝ $97.009/30/2025MRUSMerusBarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeOverweight ➝ Equal Weight$112.00 ➝ $97.009/30/2025MRUSMerusGuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy ➝ Neutral$109.00 ➝ $97.009/30/2025MRUSMerusLifesci CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform ➝ Market Perform$97.009/29/2025MRUSMerusHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Neutral$135.00 ➝ $97.00(Data available from 10/7/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCURLFCuraleaf$1.34B1.63$0.22 per share14.91$1.51 per share2.16CYTKCytokinetics$85.74M83.33N/AN/A($1.15) per share-51.92MRUSMerus$56.23M126.93N/AN/A$9.46 per share9.98RNAAvidity Biosciences$10.90M622.08N/AN/A$11.94 per share3.89Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCURLFCuraleaf-$215.42M-$0.32N/AN/AN/A-18.08%-14.61%-4.47%N/ACYTKCytokinetics-$589.53M-$5.10N/AN/AN/A-707.17%N/A-45.52%11/5/2025 (Estimated)MRUSMerus-$215.33M-$5.50N/AN/AN/A-685.64%-50.28%-42.00%10/30/2025 (Estimated)RNAAvidity Biosciences-$322.30M-$3.56N/AN/AN/A-4,247.77%-33.45%-30.22%11/6/2025 (Estimated)Latest CURLF, CYTK, MRUS, and RNA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails10/30/2025Q3 2025MRUSMerus-$1.20N/AN/AN/A$8.73 millionN/A8/7/2025Q2 2025CYTKCytokinetics-$1.34-$1.12+$0.22-$1.12$1.95 million$66.77 million8/6/2025Q2 2025CURLFCuraleaf-$0.07-$0.06+$0.01-$0.07N/AN/A8/5/2025Q1 2025MRUSMerus-$1.17-$2.23-$1.06-$2.23$9.77 million$8.83 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCURLFCuraleafN/AN/AN/AN/AN/ACYTKCytokineticsN/AN/AN/AN/AN/AMRUSMerusN/AN/AN/AN/AN/ARNAAvidity BiosciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCURLFCuraleaf1.001.470.70CYTKCytokineticsN/A6.766.76MRUSMerusN/A8.398.39RNAAvidity BiosciencesN/A9.269.26Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCURLFCuraleaf0.03%CYTKCytokineticsN/AMRUSMerus96.14%RNAAvidity BiosciencesN/AInsider OwnershipCompanyInsider OwnershipCURLFCuraleafN/ACYTKCytokinetics3.40%MRUSMerus3.70%RNAAvidity Biosciences3.83%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCURLFCuraleaf5,519670.70 millionN/ANot OptionableCYTKCytokinetics250119.66 million115.59 millionOptionableMRUSMerus3775.63 million72.84 millionOptionableRNAAvidity Biosciences190145.90 million140.32 millionOptionableCURLF, CYTK, MRUS, and RNA HeadlinesRecent News About These CompaniesAnalysts Set Avidity Biosciences, Inc. (NASDAQ:RNA) PT at $68.32October 7 at 2:43 AM | americanbankingnews.comAvidity Biosciences (RNA): Assessing Valuation Following Recent Positive Share Price MomentumOctober 6 at 11:57 AM | finance.yahoo.comAvidity Biosciences to Present Data from EXPLORE44® Clinical Development Program of Del-Zota in DMD44 at 30th Annual Congress of the World Muscle SocietyOctober 6 at 9:00 AM | prnewswire.comAvidity Biosciences, Inc. (NASDAQ:RNA) Given Consensus Recommendation of "Moderate Buy" by AnalystsOctober 4 at 4:37 AM | marketbeat.comAvidity Biosciences (NASDAQ:RNA) Shares Down 7.6% - Here's What HappenedSeptember 29, 2025 | marketbeat.comAssenagon Asset Management S.A. Has $507,000 Position in Avidity Biosciences, Inc. $RNASeptember 28, 2025 | marketbeat.comAnalysts Are Bullish on Top Healthcare Stocks: Avidity Biosciences (RNA), Crinetics Pharmaceuticals (CRNX)September 24, 2025 | theglobeandmail.comAvidity Biosciences (RNA) Announces Positive One-Year Data For its, Del-ZotaSeptember 24, 2025 | msn.comSteven George Hughes Sells 2,208 Shares of Avidity Biosciences (NASDAQ:RNA) StockSeptember 24, 2025 | insidertrades.comAvidity Biosciences (NASDAQ:RNA) Insider Sells $89,600.64 in StockSeptember 23, 2025 | marketbeat.comEvercore ISI Cuts Avidity Biosciences (NASDAQ:RNA) Price Target to $65.00September 22, 2025 | marketbeat.comWhat is Roth Capital's Estimate for RNA Q3 Earnings?September 20, 2025 | marketbeat.comRoth Capital Initiates Coverage of Avidity Biosciences (RNA) with Buy RecommendationSeptember 18, 2025 | msn.comAvidity Biosciences (NASDAQ:RNA) Coverage Initiated at Roth CapitalSeptember 18, 2025 | marketbeat.comMirador Capital Partners LP Has $1.18 Million Position in Avidity Biosciences, Inc. $RNASeptember 18, 2025 | marketbeat.comVoya Investment Management LLC Has $9.81 Million Stake in Avidity Biosciences, Inc. $RNASeptember 17, 2025 | marketbeat.comAvidity raises $690m to advance RNA pipeline and Duchenne therapySeptember 16, 2025 | thepharmaletter.comTAvidity Biosciences (NASDAQ:RNA) Trading Down 5.3% - Here's What HappenedSeptember 16, 2025 | marketbeat.comBank of America Issues Positive Forecast for Avidity Biosciences (NASDAQ:RNA) Stock PriceSeptember 16, 2025 | marketbeat.comAvidity Biosciences, Inc. Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional SharesSeptember 15, 2025 | prnewswire.comRhumbline Advisers Has $4.86 Million Stock Position in Avidity Biosciences, Inc. $RNASeptember 15, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCURLF, CYTK, MRUS, and RNA Company DescriptionsCuraleaf OTCMKTS:CURLF$3.27 +0.13 (+4.00%) As of 12:59 PM EasternCuraleaf Holdings, Inc. operates a cannabis operator in the United States. It operates through two segments, Domestic Operations and International Operations. The company offers flower, pre-rolls, flower pots, and dry-herb vaporizer cartridges; concentrates for vaporizing which includes pre-filled vaporizer cartridges and disposable vaporizer pens; and concentrates for dabbing, such as mints, distillate droppers, mints, topical balms and lotions, tinctures, lozenges, capsules, and edibles. It also provides hemp-based products and cannabinoids, such as cannabidiol and cannabigerol. In addition, the company engages in the cultivation, production, and sale of cannabis products through retail and wholesale channels. The company is headquartered in New York, New York.Cytokinetics NASDAQ:CYTK$59.70 -0.94 (-1.54%) As of 01:23 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase I clinical trial; and aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated has a strategic alliance with Ji Xing Pharmaceuticals Limited. The company was incorporated in 1997 and is headquartered in South San Francisco, California.Merus NASDAQ:MRUS$94.37 +0.10 (+0.10%) As of 01:23 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; collaboration with Incyte Corporation for the development of MCLA-145; and collaboration with Gilead Sciences, Inc. to discover novel antibody-based trispecific T-cell engagers. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.Avidity Biosciences NASDAQ:RNA$46.48 +0.30 (+0.64%) As of 01:23 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Avidity Biosciences, Inc., a biopharmaceutical company, engages in the delivery of RNA therapeutics. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat diseases previously untreatable with RNA therapeutics. The company's lead product candidate AOC 1001 for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease that is in phase 1/2 clinical trial. Its other products in pipeline include AOC 1044 for the treatment of duchenne muscular dystrophy, which is under phase 1/2 clinical development trial; and AOC 1020 to treat facioscapulohumeral muscular dystrophy that is in phase 1/2 clinical trial. The company is developing products for rare skeletal muscle and rare cardiac diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Joby's Stock Rallies as Public Flights Validate Global Game Plan SharkNinja Is Flashing a Buy Signal the Market Is Ignoring Why Semtech Stock Is Rallying After Its NVIDIA Setback Marvell Insiders Buy Shares—Should Investors Follow Suit? TrumpRx Brings Pfizer Into the Green—Is It a Buy? Behind D-Wave's Massive Week (And Why Rivals Also Popped) Eli Lilly Stock Soars on Trump Tariff Hopes and Pfizer Deal 2 Defense Stocks Riding 2025’s Massive Momentum Wave Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
